Survival rates of children with cancer continue to increase

Date:
Prinses Máxima Centrum, onderzoek, overlegingskans

The survival rate of children with cancer continues to rise, according to figures published by IKNL. Healthcare professionals and scientists at the Princess Máxima Center remain committed to curing even more children with cancer and improving the quality of life of children and survivors.

Compared to the period 1990-1999, the survival rate of children diagnosed with cancer in 2010 through 2018 is markedly higher. For diagnoses during the latter period, the survival rate was 84 percent, up from 74 percent in the 1990s.

‘It is good to see that survival in childhood cancer has continued to increase,’ Prof. Dr. René Medema, Chief Scientific Officer, says of the new IKNL figures. ‘In several forms of leukemia, such as AML and ALL, we see the largest increase thanks to a sum of many different improvements. But across the board, there are still too many children with an extremely poor prognosis: the most difficult-to-treat tumors remain. That is why it is so important to continue to join forces of healthcare professionals and researchers within the Netherlands, within Europe and worldwide. Only together can we achieve the breakthroughs needed to cure all children with cancer, with optimal quality of life.’

Following the new figures, pediatric oncologist dr. Wouter Kollen and pediatric neurosurgeon prof. dr. Eelco Hoving gave an interview to the AD newspaper. Among other things, they talked about the strides being made with immunotherapy for treatment of leukemia, how new technology lets doctors operate better, and approaches to permanently improve the quality of life of children and survivors.

IKNL’s full press release can be found here. The AD interview is here.

hardloopsymposium 2026

Full of energy toward the Utrecht Marathon: a successful running symposium filled with tips and inspiration

On March 19, the running symposium took place at UMC Utrecht, located at Utrecht Science Park, in the lead-up to the Utrecht Marathon on May 31. Many running enthusiasts who work or study at Utrecht Science Park attended the event that evening.

GenDx and Treos Bio Announce Partnership to develop HLA-based Companion Diagnostic for PolyPEPI1018 Cancer Immunotherapy

GenDx, a Eurobio Scientific Company, based in the Netherlands, specialized in molecular diagnostics for transplantation, today announced a collaboration with Treos Bio, a UK based clinical stage
company, developing next generation of effective off-the-shelf peptide cancer immunotherapies. GenDx and Treos Bio will partner in the development and validation of an integrated companion
diagnostic (CDx) HLA-typing test for Treos Bio’s off-the-shelf peptide cancer immunotherapy candidate, PolyPEPI1018, for the treatment of microsatellite stable (MSS) colorectal cancer.

Alan Hanjalic new Dean Faculty of Science

From 1 July 2026, prof. dr. Alan Hanjalic has been appointed Dean of the Faculty of Science by the Executive Board of Utrecht University (UU). He will also be appointed professor at UU. Currently, Hanjalic is professor of Computer Science and head of the Intelligent Systems department at TU Delft.

UtrechtInc has been recognized in the Financial Times “Europe’s Leading Startup Hubs 2026” ranking.

While UtrechtInc is proud of this recognition, the real stars of the story are the entrepreneurs, researchers, and students who walk through its doors every day.